Jennison Associates
AERI

Jennison Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Jennison Associates’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-31,334
Closed -$602K – 692
2019
Q3 		$602K Sell
31,334
-769,474
-96% -$17.6M ﹤0.01% 594
2019
Q2 		$23.7M Sell
800,808
-544,191
-40% -$21M 0.02% 319
2019
Q1 		$63.9M Buy
1,344,999
+161,538
+14% +$7.11M 0.06% 187
2018
Q4 		$42.7M Sell
1,183,461
-202,750
-15% -$9.51M 0.05% 241
2018
Q3 		$85.3M Buy
1,386,211
+76,390
+6% +$4.91M 0.08% 171
2018
Q2 		$88.5M Sell
1,309,821
-191,774
-13% -$10.7M 0.09% 169
2018
Q1 		$81.5M Buy
1,501,595
+108,222
+8% +$6.05M 0.08% 181
2017
Q4 		$83.3M Sell
1,393,373
-486,240
-26% -$29.5M 0.08% 189
2017
Q3 		$91.3M Sell
1,879,613
-5,462
-0.3% -$298K 0.09% 174
2017
Q2 		$99.1M Sell
1,885,075
-1,249,841
-40% -$58.2M 0.11% 158
2017
Q1 		$142M Sell
3,134,916
-293,944
-9% -$13.1M 0.15% 100
2016
Q4 		$130M Sell
3,428,860
-135,385
-4% -$5.12M 0.14% 115
2016
Q3 		$135M Sell
3,564,245
-147,450
-4% -$3.25M 0.15% 122
2016
Q2 		$65.3M Buy
3,711,695
+21,505
+0.6% +$348K 0.07% 239
2016
Q1 		$44.9M Buy
3,690,190
+38,180
+1% +$604K 0.05% 301
2015
Q4 		$88.9M Sell
3,652,010
-112,009
-3% -$2.61M 0.09% 190
2015
Q3 		$66.8M Buy
3,764,019
+669,110
+22% +$12.1M 0.07% 247
2015
Q2 		$54.6M Buy
3,094,909
+113,708
+4% +$2.08M 0.05% 320
2015
Q1 		$93.4M Buy
2,981,201
+611,618
+26% +$17.7M 0.09% 212
2014
Q4 		$69.2M Buy
2,369,583
+2,137,858
+923% +$54.2M 0.06% 270
2014
Q3 		$4.79M Buy
231,725
+338
+0.1% +$6.66K ﹤0.01% 507
2014
Q2 		$5.73M Sell
231,387
-26,325
-10% -$456K 0.01% 502
2014
Q1 		$5.46M Buy
257,712
+848
+0.3% +$17.1K 0.01% 513
2013
Q4 		$4.61M Buy
+256,864
New +$3.35M ﹤0.01% 511

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jennison Associates's AERI Position: Q4 2019 in Review

Jennison Associates sold out of Aerie Pharmaceuticals (AERI) in Q4 2019, closing a stake of 31,334 shares — an estimated $602K sold.

Jennison Associates first reported a position in AERI in Q4 2013 and held it in 24 quarters. The position peaked at $142M in Q1 2017. 167 funds tracked by Wall St. Rank hold AERI as of Q4 2019.

  • Jennison Associates reported no remaining Aerie Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Jennison Associates sold 31,334 Aerie Pharmaceuticals shares in Q4 2019, an estimated $602K.
  • Jennison Associates first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 24 quarters.
  • Jennison Associates's Aerie Pharmaceuticals position peaked at $142M in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2019.

Based on Jennison Associates's 13F filing for Q4 2019, filed 7 Feb 2020.